Abivax (ABVX) reported a Q3 loss Monday of 2.10 euros ($2.47) per diluted share, widening from a loss of 0.87 euro a year earlier.

Total operating income for the three months ended Sept. 30 was 2 million euros, compared with 1.3 million euros a year earlier.

The company said that as of Sept. 30, it had cash and cash equivalents of 589.7 million euros, sufficient to fund cash flow requirements through Q4 2027.

Abivax shares were down 3.3% in recent premarket activity Tuesday.